Clinical trials: Injury of Liver
Hepatorenal Syndrome, Acute Kidney Injury
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
- Trial name
- NCT05875948
- Testing
- R2R01, Terlipressin
- Where
- 7 sites in United States
- Volunteers
- 95 people
- Sponsor
- River 2 Renal Corp.
Ischemia-reperfusion Injury in Liver Transplant, Early Allograft Dysfunction
Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation
The objective of the study is to evaluate the efficacy and safety of Reparixin treatment (2.772 mg/kg body weight/hour intravenous continuous infusion for 7 days) based on incidence of early allograft dysfunction within the first…
- Trial name
- NCT03031470
- Testing
- Reparixin, Control
- Where
- 7 sites in Belarus, Russia
- Volunteers
- 40 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Liver Transplant
Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients
Patients undergoing orthotopic liver transplant will experience some degree of clinical and/or biochemical hepatic dysfunction. This early injury is known as primary graft dysfunction and varies from minor abnormalities to…
- Trial name
- NCT01884038
- Testing
- treprostinil sodium
- Where
- United States
- Sponsor
- United Therapeutics
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Acute Liver Failure, Acute Liver Injury, Drug Induced
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure.
- Conditions
- Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
- Trial name
- NCT06285253
- Testing
- miroliverELAP treatment
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Miromatrix Medical Inc.
Alcoholic Hepatitis
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).
- Trial name
- AHFIRM (NCT04563026)
- Testing
- DUR-928 30 mg, DUR-928 90 mg
- Where
- 68 sites in United States, Australia and 4 more
- Volunteers
- 307 people
- Sponsor
- Durect
Acute Liver Injury
Acute Liver Injury in Patients on Dapagliflozin
To compare, by insulin use at the index date, the incidence of hospitalization for acute liver injury (ALI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of…
- Trial name
- NCT02695095
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 424,091 people
- Sponsor
- AstraZeneca
Drug-Induced Liver Injury
Risk of Acute Liver Injury in Users of Antimicrobials
Moxifloxacin is a broad-spectrum antibacterial agent used to treat common community-acquired respiratory tract infections, complicated intra-abdominal infections, and pelvic inflammatory disease.
- Trial name
- NCT01434173
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
- Where
- United States
- Volunteers
- 1,299,056 people
- Sponsor
- Bayer
Head Injury
Effect of Intrathoracic Pressure Regulation on Traumatic Brain Injury
The purpose of this study is to demonstrate proof of clinical concept that application of the Intrathoracic Pressure Regulator (ITPR) will result in an increase in Cerebral Perfusion Pressure (CPP) and a decrease in Intracranial…
- Trial name
- NCT01824589
- Testing
- -7 cm H2O ITPR, -12cm H2O ITPR
- Volunteers
- 1 people
- Sponsor
- Advanced Circulatory Systems
Lysosomal Acid Lipase Deficiency
Screening for Lysosomal Acid Lipase Deficiency
The primary outcome of this study is the development of a clinical profile of pediatric patients with LAL-D, which will enable the Sponsor to provide more focused guidance to the medical community as to which pediatric patients…
- Trial name
- NCT02926872
- Testing
- There is no intervention in the study
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Liver Diseases
YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation
The study is designed to assess the feasibility of evaluating YSPSL for the amelioration of ischemia reperfusion injury following liver transplantation by administering YSPSL into the liver graft directly ex vivo via the portal…
- Trial name
- NCT00450398
- Testing
- YSPSL
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Y's Therapeutics, Inc.
Obesity, Overweight
A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function
This is an open-label, non-randomized study to assess how VCT220 is absorbed, distributed, metabolized, and eliminated after a single oral dose.
- Trial name
- NCT06938529
- Testing
- VCT220
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Hepatocellular Carcinoma, Liver Neoplasms
A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver
The purpose of this study is to determine the maximum tolerated dose (MTD) of ThermoDox when used in combination with radiofrequency ablation (RFA) in the treatment of primary and metastatic tumors of the liver.
- Trial name
- NCT00441376
- Testing
- ThermoDox
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Imunon
Infections, Bacterial
WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 (WP2) and Workgroup 1.
- Trial name
- NCT01587768
- Testing
- Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Acetaminophen Overdose
Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection
The primary purpose of this study is determine if a new formulation of Acetadote is at least as effective as the current formulation in the prevention and treatment of acetaminophen overdose related liver injury.
- Trial name
- NCT01118663
- Testing
- Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free), Acetadote
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cumberland Pharmaceuticals
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF)
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard…
- Conditions
- Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
- Trial name
- NCT06987968
- Testing
- VS-01 on top of SOC (Active Treatment Group), SOC
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Genfit
Organ Transplant, Ischemic Reperfusion Injury
PERTRIAL - Perla® Preservation Solution
Perla® is a Cold Preservation Solution, with purpose to wash out, preserve during transport liver and kidney grafts in optimal conditions from the donor to the recipient.
- Trial name
- NCT05194306
- Testing
- Perla® Cold Preservation solution
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Advanced Life Solutions
Choline Deficiency, Liver Injury
Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support
TARA-001-301 is a Phase 2b/3 randomized Open-Label Dose-Selection study with an Open-Label Extension and randomized Double-Blind, Placebo-Controlled Study with Open-Label Extension to investigate the safety and efficacy of…
- Trial name
- THRIVE-3 (NCT06910943)
- Testing
- Choline Chloride for Injection
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 129 people
- Sponsor
- Protara Therapeutics
Subjects With Liver Function Injury, Normal Liver Function Subject
A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function
Evaluate the pharmacokinetic differences of the main metabolite 116-N1 of JT001 in subjects with mild and moderate liver function impairment and those with normal liver function, providing a basis for formulating clinical…
- Trial name
- NCT06093230
- Testing
- Deuremidevir Hydrobromide Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.